Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiotropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotropium SCHEMBL155760 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL30426594 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL1405692 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL155761 | 0.99 | CHRM3 (0.98) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL14672487 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL19581677 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL4589 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL7607795 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL440873 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Tiotropium SCHEMBL15005742 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279356-A1 | INHALER FOR THE ADMINISTRATION OF AN ANTICHOLINERGIC | BOEHRINGER INGELHEIM PHARMA (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20140116435-A1 | INHALER FOR THE ADMINISTRATION OF AN ANTICHOLINERGIC | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-05-01 | — | — | US | disclosed |
| US-20120211007-A1 | INHALER FOR THE ADMINISTRATION OF AN ANTICHOLINERGIC | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8022082-B2 | Method for the administration of an anticholinergic by inhalation | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2011-09-20 | — | — | US | disclosed |
| US-20080236579-A1 | METHOD FOR THE ADMINISTRATION OF AN ANTICHOLINERGIC BY INHALATION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | 2008-10-02 | — | — | US | disclosed |
| US-20060251586-A1 | Method for the Administration of an Anticholinergic by Inhalation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-11-09 | — | — | US | disclosed |
| US-20030235538-A1 | Actuating an inhaler containing powder of tiotropium in admixture with an excipient with an average particle size of 10-500 mu m and having a flow resistance of .01-.1 square root over kPa min/L | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279356-A1 | INHALER FOR THE ADMINISTRATION OF AN ANTICHOLINERGIC | TTK, CHRM4, DEK | CHRM3 9/4885CHRM2 10/4885CHRM1 36/4885 |
| US-20030235538-A1 | Actuating an inhaler containing powder of tiotropium in admixture with an excipient with an average particle size of 10-500 mu m and having a flow resistance of .01-.1 square root over kPa min/L | ADRB1, ADRA1A, ADRA1D | CHRM3 22/4885CHRM2 25/4885CHRM1 16/4885 |
| US-20140116435-A1 | INHALER FOR THE ADMINISTRATION OF AN ANTICHOLINERGIC | CHRM3, CHRNE, CHRM5 | CHRM3 1/4885CHRM2 4/4885CHRM1 9/4885 |
| US-20060251586-A1 | Method for the Administration of an Anticholinergic by Inhalation | CHRNE, CHRM3, CHRM5 | CHRM3 2/4885CHRM2 6/4885CHRM1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.